Competitive Technologies, Inc. Provides an Innovative Solution for Relieving Chronic Neuropathic Pain
March 15 2012 - 2:38PM
Competitive Technologies, Inc. (OTCQX:CTTC) today reconfirmed that
the growing interest in its Calmare® Scrambler Therapy™ medical
device is a function of the universal goal of finding new and
innovative methods of treating chronic pain. The Calmare device is
noninvasive and avoids habit-forming drugs.
Last June, the Institute of Medicine of the National Academies
("IOM") published its report, "Relieving Pain in America: A
Blueprint for Transforming Prevention, Care, Education, and
Research," which highlighted the staggering numbers of Americans --
at least 116 million adults -- experiencing chronic pain, at an
even more staggering cost to society -- between $560 billion and
$635 billion annually. In the ensuing nine months, there has been
an explosion of interest in finding solutions for this growing
epidemic, both in the United States and internationally.
Last month, the Senate Committee on Health, Education, Labor,
and Pensions chaired by Senator Thomas Harkin (D-IA) held a hearing
"Pain in America: Exploring Challenges to Relief," to learn more
about the issue. Sen. Harkin stated emphatically, "We need to find
new, innovative therapies that we don't know about." (The full
hearing is available for viewing at
http://www.help.senate.gov/hearings/hearing/?id=5906d585-5056-9502-5dd1-1d549d0d88f7.)
CTTC has one of those revolutionary new therapies in its
Calmare® Scrambler Therapy medical device which has been shown to
successfully treat neuropathic and cancer related pain without the
harmful side effects of powerful pain medications.
News coverage about the benefits Calmare offers is expanding.
Earlier this week, Providence, RI-based NBC 10 WJAR's health
reporter, Barbara Morse Silva, filmed a story at the new West
Warwick, RI Calmar Pain Relief clinic (http://www.cprcenters.com/)
featuring a number of patients from around the country who have
been successfully treated there with CTTC's Calmare medical
device. These patients, desperate for relief from their
debilitating pain, came to Dr. Stephen D'Amato's Rhode Island
clinic from as far away as Nevada and Michigan as well as from the
local area. Suffering from cancer pain, chemotherapy-induced
peripheral neuropathy (CIPN) and other forms of chronic neuropathic
pain, the patients were all helped by the Calmare device. (See
the story which aired March 13 online
at: http://www2.turnto10.com/lifestyles/2012/mar/13/health-check-chronic-pain-treatment-ar-963406/.)
About Competitive Technologies, Inc.
Competitive Technologies is a global leader in developing and
commercializing innovative products and technologies. CTTC is
multifaceted, providing distribution, patent and technology
transfer, sales and licensing services. CTTC's staff is
focused on the needs of customers and matching those requirements
with commercially viable products or technology solutions.
CTTC is the licensed worldwide distributor of the non-invasive
Calmare® pain therapy medical device, which incorporates the
biophysical "Scrambler Therapy™" technology developed in Italy by
CTTC's client, Professor Giuseppe Marineo to treat neuropathic
pain, including cancer pain. The Calmare® device is currently
being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of
Seoul, Korea. For more information on the device, visit
www.calmarett.com. Visit CTTC's website:
www.competitivetech.net.
Statements made about our future expectations are
forward-looking statements and subject to risks and uncertainties
as described in our most recent Annual Report on Form 10-K for the
year ended July 31, 2010, filed with the SEC on October 27, 2010,
and other filings with the SEC, and are subject to change at any
time. Our actual results could differ materially from these
forward-looking statements. We undertake no obligation to update
publicly any forward-looking statement.
CONTACT: Jean Wilczynski
IR Services, LLC
(860.434.2465/info@corpirservices.com)
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Aug 2023 to Aug 2024